EUVIMEDEUVIMED entdecken
Crossref

A Rofecoxib‐Derived Theranostic Probe and Its Combination With PD‐1 Inhibitor for High‐Efficiency Cancer Therapy

Xinli Wang, Xia Wang, Xuejing Su, Zexin Wang, Yongxiao Sun, Lijun Xie iD, Xiaoyan Lin

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Xinli Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China. Hauptthemen laut MEDLINE: Lactones, Cyclooxygenase 2 Inhibitors, Sulfones, Immune Checkpoint Inhibitors. Die Arbeit nennt 36 Literaturangaben. Gefördert von: This study was supported by Joint Funds for the Innovation of Science and Technology, Fujian Province (2023Y9166)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of theranostic probes with tumor‐specific targeting and high therapeutic efficacy remains a pivotal challenge in precision oncology. Herein, we have successfully developed a new cyclooxygenase‐2 (COX‐2)‐targeted probe compound 2 derived from Rofecoxib. Compound 2 facilitated tumor visualization by a sixfold fluorescence enhancement upon COX‐2 binding, while it exhibited minimal background fluorescence under physiological conditions. Moreover, compound 2 monotherapy achieved 53% tumor regression ( p < 0.01). When combined with a programmed cell death protein 1 (PD‐1) inhibitor (RMP1‐14), concurrent blockade of the COX‐2/prostaglandin E2 (PGE2) and PD‐1/programmed death‐ligand 1 (PD‐L1) axes achieved 95% tumor regression ( p < 0.001). Compound 2 involves activating fluorescence by targeting tumor markers COX‐2 as well as enhancing therapeutic efficacy. We believe this approach could provide insights for advancing cancer diagnosis and treatment technologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LactonesCyclooxygenase 2 InhibitorsSulfonesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAntineoplastic AgentsNeoplasmsHumansAnimalsMiceTheranostic NanomedicineMolecular StructureCyclooxygenase 2Cell Line, TumorStructure-Activity RelationshipDose-Response Relationship, DrugDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

Rofecoxibcancercyclooxygenase‐2 (COX‐2)fluorescenceprogrammed cell death protein 1 (PD‐1)theranostic probe

Substanzen

rofecoxibLactonesCyclooxygenase 2 InhibitorsSulfonesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCyclooxygenase 2Antineoplastic AgentsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
  • Fujian Provincial Key Laboratory of Screening for Novel Microbial Products, Fujian Institute of Microbiology, Fuzhou, Fujian, People's Republic of China.
  • College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian, People's Republic of China.

ORCID-Profile: Lijun Xie

Förderung

  • This study was supported by Joint Funds for the Innovation of Science and Technology, Fujian Province (2023Y9166).

Zitieren

APA

Wang, X., Wang, X., Su, X., Wang, Z., Sun, Y., Xie, L., & Lin, X. (2025). A Rofecoxib‐Derived Theranostic Probe and Its Combination With PD‐1 Inhibitor for High‐Efficiency Cancer Therapy. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70155

Vancouver

Wang X, Wang X, Su X, Wang Z, Sun Y, Xie L, et al. A Rofecoxib‐Derived Theranostic Probe and Its Combination With PD‐1 Inhibitor for High‐Efficiency Cancer Therapy. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70155

BibTeX
@article{Wang2025,
  author = {Wang, Xinli and Wang, Xia and Su, Xuejing and Wang, Zexin and Sun, Yongxiao and Xie, Lijun and Lin, Xiaoyan},
  title = {A Rofecoxib‐Derived Theranostic Probe and Its Combination With PD‐1 Inhibitor for High‐Efficiency Cancer Therapy},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70155}
}
Kostenlos starten →